Researchers Optimistic about Genomics Funding, Rate Illumina and Life Tech Best in Class | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Despite a gray forecast for National Institutes of Health funding, researchers have a relatively positive outlook on genomics funding, a recent survey conducted jointly by GenomeWeb and investment firm Mizuho Securities has found.

Respondents to the survey also ranked Illumina, Life Technologies, and Roche as the companies with the best products in genomics research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.